ArticleAmerican heart journal plus : cardiology research and practice2025
Leveraging institutional echocardiographic registry to assess clinical profiles and outcomes in tricuspid regurgitation.
Article in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tricuspid regurgitation (TR) is a common valvular heart disease that is associated with increased morbidity and mortality. We utilized our large institutional echocardiographic registry, integrated with the electronic medical record-based health system registry to identify patients with varying degrees of TR, and to assess its association with long-term outcomes. Patients were categorized by TR severity as none, mild, moderate, or severe. A total of 88,511 unique individuals were included (44.7 % no reported TR, 49.0 % mild, 4.8 % moderate, and 1.5 % severe). Greater TR severity was associated with advanced age, female sex, and Black race, alongside higher prevalence of baseline comorbidities. Patients with moderate or severe TR exhibited worse congestion biomarkers, creatinine, liver enzymes, and reduced platelet counts. Echocardiographically, moderate or severe TR correlated with lower tricuspid annular plane systolic excursion, left ventricular ejection fraction, as well as larger biatrial and left ventricular volumes. There was a significant association between increasing TR severity and all-cause mortality at 3 years from the index echocardiogram compared with no TR (Moderate TR: AdjHR 1.76; 95 % CI 1.63-1.89; Severe TR: AdjHR 2.40; 95 % CI 2.16-2.66), and similarly for hospitalization (Moderate TR: AdjHR 1.14; 95 % CI 1.08-1.20; Severe TR: AdjHR 1.25; 95 % CI 1.15-1.36). In this large cross-sectional analysis, we highlight how institutional echocardiographic registries can be leveraged to identify the burden of TR, including its significant association with higher mortality and healthcare utilization. These findings emphasize the need for heightened clinical attention and potential intervention in patients with significant TR as tricuspid valve therapies evolve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.